GlassScriptPhysician profile
Ernest Terranova
NPI 1093746448
$1,565.03
in general payments reported to CMS, 2019-2025
8 companies · $79.35 in 2025
The $79.35 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $565 · 2021: $34.23 · 2022: $122 · 2023: $435 · 2024: $329 · 2025: $79.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $843.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $374.38 | 2023-2024 | Rexulti |
| Mylan Specialty L.P. | $310.44 | 2023 | Yupelri |
| Janssen Pharmaceuticals, INC | $234.90 | 2019 | |
| Acadia Pharmaceuticals INC | $208.78 | 2019-2024 | Nuplazid |
| Avanir Pharmaceuticals, INC. | $125.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $121.96 | 2022 | |
| Lilly USA, LLC | $110.22 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $79.35 | 2025 | Crexont |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ernest Terranova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.